The approved indication is specific: polylaminin therapy for patients with incomplete spinal cord injuries classified as ASIA B, C, or D, who are between 6 months and 5 years post-injury. Patients with complete spinal cord transection (ASIA A) are excluded from the current approval, as the Phase III trial did not include enough ASIA A patients to demonstrate efficacy in this population.
The treatment will initially be available at five certified neurosurgical centers. Each treatment cycle involves a single image-guided injection of polylaminin directly into the injury site, performed under general anesthesia. The procedure takes approximately 90 minutes, with a 48-hour hospital observation period.
The estimated cost per treatment cycle is R$85,000 (approximately $15,000 USD). ANVISA has recommended that the Brazilian public health system (SUS) include polylaminin in its formulary, which would make it available at no cost to qualifying patients. The Ministry of Health is expected to make a coverage decision by September 2026.
The ANVISA approval immediately attracted international attention. The US Food and Drug Administration (FDA) reportedly reached out to the Brazilian research team within 48 hours of the announcement to discuss potential expedited review pathways. The European Medicines Agency (EMA) issued a statement noting that it was "following developments with great interest."
Japan's Pharmaceuticals and Medical Devices Agency (PMDA), which has historically been more receptive to regenerative therapies than Western regulators, announced plans to fast-track review of polylaminin under its conditional approval system for regenerative medicines.
The fact that this breakthrough came from Brazil — rather than the US, Europe, or Japan — is significant. Brazilian neuroscience research has been consistently underfunded relative to the country's scientific talent pool, and the polylaminin program survived multiple funding crises over its 15-year development. Dr. Cristante has publicly credited FAPESP (the São Paulo Research Foundation) and persistent support from HC-FMUSP's institutional leadership for keeping the program alive during periods when federal research funding was cut.
The success also highlights a broader trend: countries outside the traditional biomedical research powerhouses are increasingly producing world-class innovations, often in areas that large pharmaceutical companies have deprioritized due to small market size or long development timelines.
Brazil records approximately 11,000 new spinal cord injuries per year, primarily from traffic accidents (42%), falls (27%), and violence (including gunshot wounds, 24%). The majority of victims are young men aged 18–35, and the economic burden — including lost productivity, lifetime care costs, and disability payments — exceeds R$12 billion annually.
For these patients and their families, polylaminin represents something that has been absent from spinal cord injury medicine for decades: hope grounded in evidence. Not a miracle cure, not an experimental procedure requiring travel to an overseas clinic, but a rigorously tested, domestically developed treatment approved by their own regulatory authority.
The road ahead remains long. Polylaminin doesn't restore full function, and many patients who receive it won't experience dramatic improvement. But in a field where the standard of care has been essentially unchanged since the 1970s — stabilize the spine, manage complications, and rehabilitate whatever function remains — any treatment that demonstrably improves neurological outcomes represents a genuine revolution.
